

ASX Announcement

Final Share Purchase Plan Allotment

Sydney, Australia, 28 August 2025: Imugene Limited (ASX: IMU) (Imugene or Company) is pleased to announce completion of the Share Purchase Plan, which was announced by the Company on 16 July 2025 (SPP), closed on Monday, 25 August 2025. The SPP follows on from the successful completion of the institutional placement on 16 July 2025, which raised \$22.5 million at the same issue price as the SPP (of \$0.33 per share).

The SPP raised a total of \$2.42 million from the issue of 7,335,608 fully paid ordinary shares (**New Shares**) at \$0.33 per Share. New Shares subscribed for under the SPP (and the Attaching Options and Piggyback Options) were subject to Shareholder Approval, which was received at the Company's EGM on 20 August 2025.

New Shares subscribed for under the SPP (and Attaching Options) will be issued on 1 September 2025.

Imugene's CEO and Managing Director Leslie Chong said: "We thank those investors who participated in the share purchase plan for their continued support of the Company."

Subscription Agreement

In accordance with the Subscription Agreement between the Company and CVI Investments, Inc. dated 23 December 2024, the resulting exercise price for the Warrants issued under the Warrant Deed Poll dated 23 December 2024 is \$0.33.

For more information please contact:

Leslie Chong
Managing Director and Chief Executive Officer
info@imugene.com

General Investor Enquiries
shareholderenquiries@imugene.com



Media Enquiries

Matt Wright

matt@nwrcommunications.com.au

Connect with us on LinkedIn @Imugene Limited

Follow us on Twitter @TeamImugene

Watch us on YouTube @ImugeneLimited

About Imugene (ASX:IMU)

Imugene is a clinical stage immuno-oncology company developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumours. Our unique platform technologies seek to harness the body's immune system against tumours, potentially achieving a similar or greater effect than synthetically manufactured monoclonal antibody and other immunotherapies. Our pipeline includes an off-the-shelf (allogeneic) cell therapy CAR T drug azer-cel (azercabtagene zapreleucel) which targets CD19 to treat blood cancers. Our pipeline also includes oncolytic virotherapy (CF33) aimed at treating a variety of cancers in combination with standard of care drugs and emerging immunotherapies such as CAR T's for solid tumours and B-cell vaccine candidates. We are supported by a leading team of international cancer experts with extensive experience in developing novel cancer therapies that are currently marketed globally. Our vision is to help transform and improve the treatment of cancer and the lives of the millions of patients who need effective treatments. This vision is backed by a growing body of clinical evidence and peer-reviewed research. Together with leading specialists and medical professionals, we believe Imugene's immuno-oncology therapies will become foundation treatments for cancer. Our goal is to ensure that Imugene and its shareholders are at the forefront of this rapidly growing global market.

Release authorised by the Managing Director and Chief Executive Officer Imugene Limited.

Not an offer in the United States



This announcement has been prepared for publication in Australia and may not be released to US wire services or distributed in the United States. This announcement does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States or any other jurisdiction. Any securities described in this announcement have not been, and will not be, registered under the US Securities Act of 1933 and may not be offered or sold in the United States except in transactions exempt from, or not subject to, the registration requirements under the US Securities Act and applicable US state securities laws.